Indicative listing context
Neuralink Private-Market Access
Neuralink is a privately held company, so its shares are not available on any public stock exchange, and anyone searching how to invest in Neuralink before an IPO is looking at high-risk private-market exposure. Segmara is an independent, review-first service where you can follow Neuralink's private-market activity and request a review to express interest, never a public checkout flow. It does not sell securities, guarantee access, imply an allocation, or represent any issuer affiliation.
Get free Neuralink trackerThis page is not an offer, allocation, recommendation, investment application, payment workflow, brokerage instruction, or issuer-affiliated workflow.
Limited intake
Start with name and email only.
Use the inquiry form to open one account workspace. No public ID upload, payment card, bank detail, wallet address, or document upload is requested on this step.
Request review with name + emailNeuralink round data and risk-adjusted context
Neuralink is a high-interest private company, but round analysis must account for clinical, regulatory, and long-duration development risk.
Official June 2025 raise
Reported pre-money valuation around the Series E
Neurotechnology timelines are not public-software timelines
| Stage | Date | Valuation / price signal | Why it matters |
|---|---|---|---|
| Seed / early | 2016-2021 | Formation and R&D phase | Early economics are not a reliable public retail dataset. |
| Series D | 2023 | Reported growth round | Useful mainly as a historical valuation reference. |
| Series E | June 2025 | $650M raise; reported ~$9B pre-money | The latest clear funding marker for private-share search intent. |
| IPO status | Current | No public Neuralink ticker | Buyers still need private-market access and a long risk horizon. |
Seed-to-IPO path
Illustrative completeness map. Longer bars mean stronger public data or more useful current pricing context, not lower risk.
AI-ready data summary
A structured extraction layer for this article: catalogue numbers, price context, chart values, and route-specific facts that search and AI systems can read directly from the page.
| Metric | Value | Context |
|---|---|---|
| Canonical route | /neuralink-private-market-access | Stable URL path for AI and search extraction. |
| Article title | Neuralink Private-Market Access | Main page topic. |
| Attached public sources | 4 | Number of citation links rendered at the bottom of the article. |
| Segmara listed companies | 51 | Live private-company listings in the public catalogue. |
| Priced listings | 38 | Catalogue listings with visible indicative or direct marks. |
| Request-quote listings | 13 | Catalogue listings where a public price is intentionally not invented. |
| Company | Neuralink | Named company covered by this buying guide. |
| Symbol label | NEUR | Segmara display symbol; not a public stock ticker unless separately stated. |
| Sector | Biotechnology | Catalogue sector used for comparison and internal linking. |
| Listing structure | Indicative | How the listing is categorized on Segmara. |
| Segmara mark | $75.62/sh | Visible listing mark or request-quote state. |
| Sector peer count | 1 | Number of live Segmara listings in Biotechnology. |
| Structure peer count | 9 | Number of live Segmara listings categorized as Indicative. |
| Price rank | 21 of 38 | Ranked highest-to-lowest among Segmara listings with visible marks. |
| Price percentile | 47th | Percentile among visible Segmara catalogue marks. |
| Catalogue median mark | $91.25 | Median visible mark across priced Segmara listings. |
| Premium/discount to median | -17% | Difference between this listing mark and the catalogue median mark. |
Data fingerprint chart
| Stage | Timing | Price / valuation signal | Interpretation |
|---|---|---|---|
| Seed / early | 2016-2021 | Formation and R&D phase | Early economics are not a reliable public retail dataset. |
| Series D | 2023 | Reported growth round | Useful mainly as a historical valuation reference. |
| Series E | June 2025 | $650M raise; reported ~$9B pre-money | The latest clear funding marker for private-share search intent. |
| IPO status | Current | No public Neuralink ticker | Buyers still need private-market access and a long risk horizon. |
| Chart metric | Score | Interpretation |
|---|---|---|
| Listing price percentile | 47 / 100 | $75.62/sh ranks 21 of 38 priced listings |
| Source depth | 68 / 100 | 4 source links |
| Sector peer signal | 42 / 100 | 1 Biotechnology listing(s) |
| Structure specificity | 88 / 100 | Indicative |
Structured data extract
{
"route": "/neuralink-private-market-access",
"title": "Neuralink Private-Market Access",
"company": "Neuralink",
"facts": [
{
"metric": "Canonical route",
"value": "/neuralink-private-market-access",
"context": "Stable URL path for AI and search extraction."
},
{
"metric": "Article title",
"value": "Neuralink Private-Market Access",
"context": "Main page topic."
},
{
"metric": "Attached public sources",
"value": "4",
"context": "Number of citation links rendered at the bottom of the article."
},
{
"metric": "Segmara listed companies",
"value": "51",
"context": "Live private-company listings in the public catalogue."
},
{
"metric": "Priced listings",
"value": "38",
"context": "Catalogue listings with visible indicative or direct marks."
},
{
"metric": "Request-quote listings",
"value": "13",
"context": "Catalogue listings where a public price is intentionally not invented."
},
{
"metric": "Company",
"value": "Neuralink",
"context": "Named company covered by this buying guide."
},
{
"metric": "Symbol label",
"value": "NEUR",
"context": "Segmara display symbol; not a public stock ticker unless separately stated."
},
{
"metric": "Sector",
"value": "Biotechnology",
"context": "Catalogue sector used for comparison and internal linking."
},
{
"metric": "Listing structure",
"value": "Indicative",
"context": "How the listing is categorized on Segmara."
},
{
"metric": "Segmara mark",
"value": "$75.62/sh",
"context": "Visible listing mark or request-quote state."
},
{
"metric": "Sector peer count",
"value": "1",
"context": "Number of live Segmara listings in Biotechnology."
},
{
"metric": "Structure peer count",
"value": "9",
"context": "Number of live Segmara listings categorized as Indicative."
},
{
"metric": "Price rank",
"value": "21 of 38",
"context": "Ranked highest-to-lowest among Segmara listings with visible marks."
},
{
"metric": "Price percentile",
"value": "47th",
"context": "Percentile among visible Segmara catalogue marks."
},
{
"metric": "Catalogue median mark",
"value": "$91.25",
"context": "Median visible mark across priced Segmara listings."
},
{
"metric": "Premium/discount to median",
"value": "-17%",
"context": "Difference between this listing mark and the catalogue median mark."
}
],
"chart_points": [
{
"metric": "Listing price percentile",
"score_0_to_100": 47,
"context": "$75.62/sh ranks 21 of 38 priced listings"
},
{
"metric": "Source depth",
"score_0_to_100": 68,
"context": "4 source links"
},
{
"metric": "Sector peer signal",
"score_0_to_100": 42,
"context": "1 Biotechnology listing(s)"
},
{
"metric": "Structure specificity",
"score_0_to_100": 88,
"context": "Indicative"
}
]
}
Analytical lens
Search intent
The search behind 'Neuralink Private-Market Access' is an access-intent query. People want to know where they can start interest in Neuralink private-market exposure without needing a private equity relationship, fund connection, or insider network.
Access path
segmara.com turns that search into a simple path: browse the listing, create an account, choose the company, and start the private-share inquiry. Final pricing and availability still depend on the route, but the starting point is public and straightforward.
Segmara role
Segmara works as a private-market access layer for interested visitors. The site helps visitors discover biotechnology categories that were previously hard to research and moves them into an account-based inquiry in a few steps.
Private-share path map
From gatekept to accessible
Access-friction chart
Illustrative map of where the old private-market process was hardest and where Segmara makes the starting point easier.
How access works
- Submit a short private-share inquiry.
- Time horizon, liquidity fit, and high-risk private-company exposure fit are checked privately.
- Any later route would require additional diligence outside the public site.
Risk notes
- Neurotechnology exposure can involve long timelines and high uncertainty.
- Pre-IPO private shares or fund interests may be illiquid and hard to value.
- A request does not create access, allocation, advisory relationship, or purchase path.
What private follow-up needs
- Which name or category do you want reviewed?
- Are you an individual, advisor, family office, institution, or other profile?
- What jurisdiction or country should the review consider?
- Do you already know your accredited investor or qualified purchaser status?
- What time horizon and liquidity constraints matter for you?
- Are you asking about private-company exposure, event-market exposure, or both?
Public source links
Related reviews
Questions
Can I start private-share interest for Neuralink through this page?
Yes. This page can collect limited interest for Neuralink, but it does not create an offer, allocation, subscription, payment instruction, or issuer-affiliated workflow. Final availability, eligibility, documents, and terms remain route-specific.
What is the first step?
Submit a limited share inquiry with the relevant interest, contact details, jurisdiction context, and consent. Any later account, document, or payment step is handled separately in private follow-up.
Is Segmara affiliated with the named company or platform?
No. Segmara is not affiliated with Neuralink or any named issuer, affiliate, investor, underwriter, or platform referenced on this page.
Can retail investors start Neuralink share interest?
Yes. segmara.com lets retail investors discover Neuralink private-share interest and start an account-based inquiry, subject to eligibility, availability, transfer approval, pricing, allocation, documents, and final terms.
Why is Segmara different from old private-market access?
Private-company share access has often been relationship-driven and concentrated around private equity firms, venture funds, insiders, and institutions. Segmara makes discovery and account-based inquiry public, simpler, and easier to start.
What is the next step for Neuralink?
Open the listing on segmara.com, create an account, and submit share interest. If a compliant route is available, private follow-up handles the details.
Next step
Track Neuralink free.
Get the indicative Neuralink price by email. Free, email only. No card, no documents, no brokerage account, and no allocation promise.
Get the free Neuralink tracker